Skip to main content

Table 1 Patient characteristics and MK-1775 sensitivity for primary AML patient samples

From: CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells

Patient

Gender

Age (year)

Disease status

FAB subtype

WBC (×103/μL)

Blast purity (%)

Cytogenetics

MK-1775 IC50(nM)

AML#0

Female

13

At diagnosis

M2

39.9

79

46, XX, t(8;21)(q22;q22)

5996.5

AML#1

Female

50

At diagnosis

M4

22.66

52

46, XX, del(5q), add(12p)

2448.5

AML#2

Male

20

At diagnosis

M2

23.55

42

45, X, -Y, t(8;21)(q22;q22)

3204.0

AML#3

Male

4

At diagnosis

M3

4.71

75

46, XY, t(15;17)(q22;q21)

461.0

AML#4

Male

55

At relapse

M2

5.64

14

46, XY, t(8;21)(q22;q22)

844.0

AML#5

Female

57

At relapse

M2

22.16

70

46, XX

948.3

AML#6

Male

60

At diagnosis

M3

1.83

86

46, XY, t(15;17)(q22;q21)

233.7

AML#7

Female

53

At relapse

M4

3.87

36

46, XX

325.0

AML#8

Male

55

At diagnosis

M2

3.87

32

46, XY

887.9

AML#9

Female

35

At relapse

M5

17.71

87

47, XX, +10, t(16;21)(p11;q22), add(11p)

744.4

AML#10

Male

23

At diagnosis

M2

25.89

53

46, XY, del(9q)

439.7

AML#11

Female

43

At diagnosis

M2

25.12

91

46, XX

411.3

AML#12

Male

6

At diagnosis

M3

93.99

85

46, XY, t(15;17)(q22;q21)

277.5

AML#13

Male

52

At diagnosis

M2

1.65

27

46, XY, t(11;15;17)(q25;q15;q21)

3579.5

AML#14

Female

18

At diagnosis

M3

1.62

64

46, XX

9113

AML#15

Female

63

At diagnosis

M2

0.6

23

46, XX

344.1

AML#16

Male

38

At diagnosis

M3

2.27

90

46, XY, t(15;17)(q22;q21)

216.9

AML#17

Female

45

At diagnosis

M4

1.52

36

46, XX

3473.0

AML#18

Female

19

At relapse

M2

21.55

52

46, XX, t(8;21)(q22;q22)

1187.0

AML#19

Male

4

At diagnosis

M4

77.32

41

46, XY

5587.0

AML#21

Male

42

At diagnosis

M4

10.60

51

46, XY/44, XY, -17, -19, (11q-?)

1176.0

AML#22

Female

47

At diagnosis

M5

244.53

80

46, XX

1255.0

AML#23

Male

60

At diagnosis

M5

2.10

81

46, XY, +2, +8, I(12)(q10)

1480.0

AML#25

Female

12

At diagnosis

M3

5.11

88

46, XX, t(15;17)(q22;q21)

615.1

AML#26

Male

59

At diagnosis

M2

129.98

81

46, XY

5868.0

AML#27

Female

41

At relapse

M4

40.20

24

47, XX,del(5q),+8,t(15;18)(q12,q23)

6384.0

AML#29

Male

9

At diagnosis

M4

68.14

31

46, XY, t(6;9)(p22;q34)

880.4

AML#31

Male

17

At diagnosis

M2

12.94

69

46, XY

453.7

AML#32

Female

76

At diagnosis

M5

13.93

85

46, XX

2888.0